This article was originally published in The Gray Sheet
Executive SummaryAcquires EyeTech Vision A.G.' s Krumeich-Barraquer microkeratome, an instrument used to create the corneal flap in laser in situ keratomileusis procedures, Summit says Oct. 29. The company will assume international sales responsibilities immediately; release in the U.S. is expected following FDA clearance of a pending 510(k). Twenty-five of the devices, which sell for between $55,000-$60,000 each, have been sold in fourteen countries outside the U.S., Summit notes. The system is the only microkeratome device "that has critical surgical parameters controlled by a computer system," Summit claims
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.